- Home
- HAFN vs ADPT Comparison
HAFN vs ADPT Comparison
Compare HAFN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | ADPT |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HAFN | ADPT |
|---|---|---|
| Price | $6.67 | $13.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $17.78 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 8.21% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $3.61 | $6.68 |
| 52 Week High | $7.96 | $20.76 |
Technical Indicators
Market Signals| Indicator | HAFN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 39.69 | 30.42 |
| Support Level | $6.01 | $12.32 |
| Resistance Level | $7.96 | $13.45 |
| Average True Range (ATR) | 0.24 | 0.82 |
| MACD | -0.15 | -0.29 |
| Stochastic Oscillator | 8.36 | 20.71 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).